Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMW 2019 | Issues within maintenance therapy standardization in MM

Giadi Bianchi • 15 Sep 2019
IMW 2019
Multiple Myeloma

Giada Bianchi, MD, Dana-Farber Cancer Institute, Boston, MA, outlines the financial and geographical implications of the availability of maintenance therapy drugs for multiple myeloma (MM), speaking at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.

Related Videos

4:59
MRD as an endpoint for accelerating drug approval in multiple myeloma: updates from the ODAC meeting
Ola Landgren • 13 Apr 2024
1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals